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relationship between RMU and migraine symptom end points was also assessed.
RESULTS: This post hoc analysis included 794 patients randomized (1:1) to receive
double-blind treatment with MAP0004 or placebo. The primary results of the study
were previously published. Patients were well matched for demographic and base-
line characteristics. Patients receiving MAP0004 experienced statistically signifi-
cantmigraine symptom reduction comparedwith patients receiving placebo. RMU
in the double-blind periodwas consistently lower withMAP0004 thanwith placebo
at 2 hours (4% vs. 8%, P0.0261), 4 hours (19% vs 37%, P0.0001), 24 hours (36% vs.
54%, P0.0001), and 48 hours (42% vs. 59%, P0.0001) after study-drug administra-
tion. RMU was also significantly lower with MAP0004 than with placebo across
demographic and baseline characteristics. Among patients who reported pain re-
lief at 2 hours, MAP0004-treated patients had significantly lower RMU at 4, 24, and
48 hours than placebo-treated patients. The overall adverse event rate was com-
parable to that of placebo. CONCLUSIONS: In this study, RMU was significantly
lower with MAP0004 than with placebo overall and across demographic and base-
line characteristics.
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OBJECTIVES: To profile real world treatment patterns of patients with tuberous
sclerosis complex (TSC) which is a genetic disease that can affect multiple organ
systems in the body.METHODS:We conducted a retrospective cohort study with a
large national healthcare claims database that consists of 39 million commercially
insured Americans between 2000 and 2009. Patients with a TSC claim and contin-
uous enrollment 12 months before and 12 months after their first TSC diagnosis
were included in the study (these selection criteria lead to the exclusion of those at
age less than one). Resource utilization rates (measured as number of claims per
patient) were examined for different provider types and places of services, and
compared between the year before and after the first TSC diagnosis. Two-tail
paired sample dependent t test and Chi-square test were used for pre-post com-
parisons as well as cross-region comparison. RESULTS: The included patients
(N1249) had a mean age of 33.9 years at their first TSC diagnosis, and 57.5% were
female. Resource utilization rates with significant pre-post differences were inpa-
tient admissions (0.16 vs. 0.08, p0.01), emergency care (1.14 vs. 0.78, p0.05),
hospital outpatient care (12.68 vs. 6.66, p0.05), neurologist care (0.60 vs. 0.32,
p0.05), neurological surgeon care (0.06 vs. 0.02, p0.05), oncologist care (0.32 vs.
0.12, p0.05), and the use of anti-epilepsy medications (2.45 vs. 2.10, p0.05). The
most common places of care were physician offices (21.44), hospital outpatient
departments (12.68) and specialty care facilities (8.37); the most common provider
specialties were primary care providers (6.07), neurologists (0.60), oncologists
(0.32), surgeons (0.29); and the most common class of medications were anti-epi-
lepsymedications (2.45). Significant cross-region variations in TSCmedication uti-
lization and costs were also observed (p0.05). CONCLUSIONS: TSC patients had a
very diverse treatment profile due to its multi-organ involvement. Future research
is needed to explore the driving forces behind cross-region variations in TSC treat-
ment.
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OBJECTIVES:To investigate Parkinson’s disease (PD)medication initiation patterns
based upon diagnosing physician specialty. METHODS: Data were obtained from
the i3 InVision™ Data Mart database from January 1, 2006 through March 30, 2011.
Patients included in the analyses were diagnosed with PD (initial diagnosis identi-
fied as index date) and had continuous insurance coverage from 6 months prior
through 12 months post index date, and were at least age 35. Categorical variables
were examined using chi-square statistics while continuous variables were exam-
ined using t-tests; all are descriptive. RESULTS:A total of 5967 patients fit the study
criteria. Patients diagnosed by a neurologist (N3173), compared to those diag-
nosed by another physician specialty, were more likely to be male (58.86% vs.
53.72%; P0.0002), younger (66.53 years vs. 70.81 years; P0.0001), and in better
health, as proxied by the Charlson Comorbidity Index (1.14 vs. 1.28; P0.0034).
Patients diagnosed by a neurologist were significantly more likely to be treated
with a PD medication during the study period (48.91% vs. 30.06%; P0.0001). A
neurologist was significantly more likely to initially prescribe a monoamine
oxidase B inhibitor (MAO-B) (21.07% vs. 12.86%; P0.0001) or carbidopa/
levodopa/entacapone (9.86% vs. 6.43%; P0.0004), than a physician of another
specialty, but significantly less likely to initially prescribe carbidopa/levodopa
(27.90% vs. 42.38%; P0.0001). There was no difference in the rates of switching
from initial class of PD medication or adjunctive use of an additional class of PD
medication, although among patients prescribed multiple classes of PD medi-
cations, patients diagnosed by a neurologist were more likely to be prescribed a
dopamine agonist in combination with a MAO-B (40.08% vs. 27.34%; P0.0147).
CONCLUSIONS: These analyses found differences in treatment patterns based
upon the specialty of the diagnosing physician. Additional studies are war-
ranted to raise awareness of differences in PD treatment by diagnosing physi-
cian and to address potential health care disparities.
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OBJECTIVES: Evaluate diagnosis and treatment initiation patterns in Parkinson’s
disease (PD) based upon age. METHODS: Data were obtained from the i3 InVi-
sionTM Data Mart database from January 1, 2006 through March 30, 2011. Patients
were diagnosed with PD (initial diagnosis identified as index date), had continuous
insurance coverage from 6 months prior through 12 months post index date and
were at least 35 years old. Cohorts were divided into those under 65 and over 65
years of age. These analyses are descriptive, with continuous variables examined
using t-tests and categorical variables examined using chi-square statistics.
RESULTS: A total of 5,967 patients fit the inclusion criteria. More individuals
(58.22%) were age 65 or older, and in worse physical health, evidenced by a signif-
icantly higher pre-period Charlson score (1.52 vs. 0.77; P0.0001) and had higher
rates of pre-period cerebrovascular disease (21.53% vs. 9.07%; P0.0001), cardiovas-
cular disease (22.86% vs. 8.10%; P0.0001), dementia (10.22% vs. 1.60%; P0.0001),
diabetes (22.77% vs. 14.64%; P0.0001), hypertension (56.99% vs. 35.10%; P0.0001),
and psychoses (15.03% vs. 9.51%; P0.0001). Individuals age 65were significantly
less likely to be treatedwith PDmedication (35.69% vs. 46.21%; P0.0001), andmore
likely to be diagnosed by a neurologist (61.37% vs. 48.29%; P0.0001). Older individ-
uals were more likely to be initially prescribed carbidopa/levodopa (44.27% vs.
20.83%; P0.0001), a catechol o-methyltransferase inhibitor (5.08% vs. 2.25%;
P0.0003), or carbidopa/levodopa/entacapone (10.81% vs. 6.34%; P0.0001), but sig-
nificantly less likely to be initially prescribed a dopamine agonist (32.42% vs.
47.14%; P0.0001), amonamine oxidase B inhibitor (12.50%vs. 24.31%; P0.0001), or
an anticholinergic (3.31% vs. 6.83%; P0.0001). There was no significant difference
between rates of switching from initially prescribedmedication (18.63% vs. 21.53%;
P0.0767), although younger individuals were more likely to add an additional
class of therapy (18.40% vs. 13.15%; P0.0004). CONCLUSIONS: These analyses
highlighted potential age disparities in treatment patterns.
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OBJECTIVES: To evaluate diagnosis and treatment initiation patterns in Parkin-
son’s disease (PD) based upon patient sex.METHODS:Data used for these analyses
were obtained from the i3 InVisionTM Data Mart database from January 1, 2006
through March 30, 2011. Patients were included in the analyses if they were diag-
nosedwith PD (initial diagnosis identified as index date) had continuous insurance
coverage from6months prior through 12months post index date, andwere at least
35 years old. The analyses are descriptive, with differences in continuous variables
examined using t-tests and differences in categorical variables examined using
chi-square statistics. RESULTS: A total 5967 patients who fit the inclusion and
exclusion criteria. Results revealed significant differences based on sex. More men
(56.29%) than women were diagnosed with PD, and men were in worse overall
physical health as evidenced by a significantly higher pre-period Charlson score
(1.10 vs. 1.29; P0.0001) and higher rates of pre-period diagnoses of cardiovascular
disease (21.05% vs. 11.08%; P0.0001), diabetes (20.06% vs. 17.71%; P0.0043), and
high cholesterol (38.67% vs. 34.05%; P0.0002). Female patients, however, were
more likely to be diagnosed with mental-health comorbidities, such as anxiety
(8.93% vs. 5.45%; P0.0001), depression (16.53% vs. 11.34%; P0.0001), or psychoses
(14.46% vs. 11.37%; P0.0004). Males were significantly more likely to receive PD
medication (43.55% vs. 35.68%; P0.0001) and were more likely to be diagnosed by
a neurologist (55.31% vs. 50.42%; P0.0008). Maleswere also found to bemore likely
to be initially prescribed a monamine oxidase B inhibitor (20.16% vs. 15.07%;
P0.0016). There was no significant difference between males and females with
regards to rates of switching from initially prescribed medication (20.37% vs.
19.48%; P0.5978) or adding an additional therapy to their initial regime (16.47% vs.
14.42%; P0.1792). CONCLUSIONS: These analyses highlight potential sex dispar-
ities in treatment patterns.
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OBJECTIVES: The objective of this study was to determine if an association existed
between race/ethnicity and exposure to Alzheimer’s disease (AD) pharmacother-
apy across four state Medicaid populations. METHODS: Data from the Centers for
Medicare and Medicaid services was used in this retrospective study. Individuals
had to have an AD diagnosis (ICD-9 code 331.0) and be enrolled in a California,
Florida, New Jersey, or New York Medicaid program during 2004. Outcomes of
interest were exposure to a cholinesterase inhibitor (ChEI) or memantine. Multi-
variate logistic regression was used to test for the association between race/eth-
nicity and the exposure to a ChEI or memantine. Variables of interest included
demographic characteristics and resource utilization factors. The Oaxaca-Blinder
decomposition method to test for disparities was used to determine if exposure to
a ChEI or memantine was influenced by race. RESULTS: Approximately 158,974
individuals qualified for this study. Race, age, long-term care admittance, inpatient
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